Structural characterization of thyroglobulin type-1 domains of equistatin

被引:18
作者
Galesa, K
Pain, R
Jongsma, MA
Turk, V
Lenarcic, B
机构
[1] J Stefan Inst, Dept Biochem & Mol Biol, Ljubljana 1000, Slovenia
[2] Plant Res Int, NL-6700 AA Wageningen, Netherlands
关键词
cathepsin D; domain conformation; equistatin; papain; thyroglobulin type-1 domain;
D O I
10.1016/S0014-5793(03)00215-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Equistatin is a protein composed of three thyroglobulin type-1 domains. It inhibits papain-like cysteine proteinases and the aspartic proteinase, cathepsin D. To determine the structural basis for this inhibition we cloned and expressed the separated domains (eq d-1, eq d-2, eq d-3) in Pichia pastoris. Kinetic constants for the interaction of eq d-1 with papain and that of eq d-2 with cathepsin D are of similar order (subnanomolar) and are comparable to the constants obtained for full-length equistatin. The target proteinase for the third domain remains unknown. Thus, we demonstrate here that thyroglobulin type-1 motifs per se are able to support specific structural features that enable them to inhibit proteases from different classes. The overall conformation of three domains in equistatin is such that the interaction of domains 1 or 2 with their respective target enzymes is not hindered sterically by either domain. In addition, we show that the interaction of eq d-2 with cathepsin D results in conformational changes, which is not the case for the eq d-1/papain interaction. (C) 2003 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.
引用
收藏
页码:120 / 124
页数:5
相关论文
共 32 条
  • [1] CRYSTAL-STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN-D - IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
    BALDWIN, ET
    BHAT, TN
    GULNIK, S
    HOSUR, MV
    SOWDER, RC
    CACHAU, RE
    COLLINS, J
    SILVA, AM
    ERICKSON, JW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (14) : 6796 - 6800
  • [2] Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L
    Bevec, T
    Stoka, V
    Pungercic, G
    Dolenc, I
    Turk, V
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (04) : 1331 - 1338
  • [3] BLUMBERG S, 1970, EUR J BIOCHEM, V15, P96
  • [4] Heterologous protein expression in the methylotrophic yeast Pichia pastoris
    Cereghino, JL
    Cregg, JM
    [J]. FEMS MICROBIOLOGY REVIEWS, 2000, 24 (01) : 45 - 66
  • [5] Cloning and expression of functional equistatin
    Galesa, K
    Strukelj, B
    Bavec, S
    Turk, V
    Lenarcic, B
    [J]. BIOLOGICAL CHEMISTRY, 2000, 381 (01) : 85 - 88
  • [6] Design of sensitive fluorogenic substrates for human cathepsin D
    Gulnik, SV
    Suvorov, LI
    Majer, P
    Collins, J
    Kane, BP
    Johnson, DG
    Erickson, JW
    [J]. FEBS LETTERS, 1997, 413 (02) : 379 - 384
  • [7] Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S
    Guncar, G
    Pungercic, G
    Klemencic, I
    Turk, V
    Turk, D
    [J]. EMBO JOURNAL, 1999, 18 (04) : 793 - 803
  • [8] Folding, stability, and secondary structure of a new dimeric cysteine proteinase inhibitor
    Kidric, M
    Fabian, H
    Brzin, J
    Popovic, T
    Pain, RH
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 297 (04) : 962 - 967
  • [9] Knapp S, 1998, PROTEINS, V31, P309, DOI 10.1002/(SICI)1097-0134(19980515)31:3<309::AID-PROT7>3.0.CO
  • [10] 2-D